• iSpecimen completed the $4.5 million acquisition of two AI products from Foldlab AI on November 2, 2026.
• The products identify disease-associated proteins and predict disease trends, expanding the biospecimen marketplace into AI-powered disease intelligence.
• The purchase includes $750,000 in cash paid at closing.
• Up to $1.25 million is payable in two $625,000 milestone payments upon delivery and acceptance of applicable products.
• The remaining consideration comprises $2.5 million in common stock, totaling 2,907,977 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iSpecimen Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611051605NEWSFILECNPR____20261105_322733_1) on November 05, 2026, and is solely responsible for the information contained therein.